

Table 3. Endpoints of atomoxetine therapy

Endpoint of therapy	Number(%)
Continued atomoxetine	11 (29.7)
Received supplemental therapy due to partial response	5 (13.5)
Atomoxetine therapy discontinued	
Adverse effects	11 (29.7)
Inefficacy	8 (21.6)
Other	2 (5.4)